So, even though emerging evidence looks promising, we still need to go a long way to establish these drugs as safe and effective treatment options for type 1 diabetic patients
Yarizadh, S
Foundational texts like the Charaka Samhita and Sushruta Samhita contain these records [2]
Other oral GLP-1 medicines are being studied, including orforglipron, but these are not currently licensed in the UK for weight loss
But all too often, anxiety spirals out of control, consuming our attention, draining our energy, and revving our bodys fight-or-flight response in potentially toxic ways
Gastrointestinal adverse events increased across treatments, discontinuation was highest with semaglutide 7.2 mg, and serious adverse events were comparable to placebo